Mr McCoy is currently working as a president of McCoy Enterprises, a company responsible for development of the patented buccal mucosa oral drug delivery system for which Spring Creek signed its strategic licensing agreement on May 3, 2010.
Mr McCoy has more than 20 years of experience in scientific research and development and has helped over 225 foreign and domestic companies introduce their drug and medical device products into the US and world market. He was program manager at the Stanford Research Institute International.
Kelly Hickel, chairman and CEO of Spring Creek Capital, said: “We’re pleased to announce the addition of Randall McCoy to our board of directors, and look forward to working closely with him as we continue to expand our business operations and healthcare related services.
“With his depth of knowledge and outstanding reputation in the pharmaceutical industry, Randall will be an excellent resource as he assists Spring Creek in facilitating sub-licensing agreements for our recently acquired buccal mucosa spray technology, in addition to providing expert advice on our focused growth strategy in the healthcare markets in general.”
Mr McCoy said: “I’m honored to have the chance to work with Kelly Hickel and the rest of the Spring Creek management team. I joined the board because I believe Spring Creek has been presented with an opportunity to make great strides in advancing the patented buccal mucosa oral spray technology as we prepare to penetrate the sizable worldwide insulin markets, in addition to improving the delivery of various other drugs, including chemical entities, proteins and peptides.”